From the Chairman/CEO
In the second quarter of 2010, Cephalon continued to set new records for its success, while the most promising pipeline in the company’s history gained significant momentum.
During the quarter, sales hit $712.4 million, a 32 percent increase compared to sales in the second quarter of 2009. In addition, the adjusted net income reached $165.3 million, a 49 percent increase over the comparable period in 2009. Based on these impressive figures, we exceeded our previously issued guidance on sales and basic adjusted income per common share.
We are Cephalon
A global biopharmaceutical company driven to expand the boundaries of science to improve human health. A company with first-in-class therapeutics, a rich oncology research pipeline and medications to treat central nervous system disorders, cancer, and pain. A company dedicated to our patients, healthcare professionals, employees, and communities.
Latest News
Spreading Awareness on Safe Use
Cephalon has expanded its advocacy program to educate patients, caregivers and the public on the appropriate use of prescription medicines.Read more >>
Getting Recognized in Philadelphia
Cephalon earns top rankings among area pharmaceutical, public, and fast-growing companies in the Philadelphia Business Journal's Book of Lists.Read more >>
Making the Ranking
On the Fortune 1000 list for 2010, Cephalon rises 122 positions to 781, compared to 903, which was the company’s rank on the 2009 list.Read more >>
When Good Medicines Become
Bad DrugsSM
Experts in the pain community discuss the importance of understanding the safe and appropriate use of prescription medicines.
Margaret Hansen Frogge, RN, MS, President, ONS Foundation
On the partnership between Cephalon and the Oncology Nursing Society (ONS) Foundation. Read more >>